NK Cell immunotherapy for high‐risk neuroblastoma relapse after haploidentical HSCT

Kanold, Justyna; Paillard, Catherine; Tchirkov, Andréï; Lang, Peter; Kelly, A.; Hallé, Pierre; Isfan, Florentina; Merlin, Étienne; Marabelle, Aurélien; Rochette, Emmanuelle; Deméocq, F.

doi:10.1002/pbc.24030

Cited by 32 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite this advance and those in intensive chemotherapy, surgery, and radiation, the survival of patients remains unsatisfactory (9,10). Recently, following the success of NK cell therapy in hematologic malignancies (14,30,31), investigators have begun studying similar therapy in neuroblastoma (23,32,33). We and others have shown that several novel NK cell activation methods using various cytokine combinations such as IL-12 and -18 or using genetic modification may improve the efficacy of NK cells in preclinical models (34)(35)(36)(37).…”

Section: Discussionmentioning

confidence: 99%

Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…17 Further analysis revealed that all patients who demonstrated response were mismatched for natural killer (NK) cell KIR/KIR-ligand genotypes, there being no responses amongst KIR-matched patients. 106 A particularly promising approach is the development of genetically engineered autologous T cells, which allows a patient's own cytotoxic T cells to be redirected against tumor-associated antigens (such as GD2) by stably transfecting the cells with a chimeric antigen receptor. 100,101 Thus, in the future, it may be possible to predict those patients likely to benefit most on the basis of their pattern of disease and immunogenotype.…”

Section: Immunotherapymentioning

confidence: 99%

Current and Future Strategies for Relapsed Neuroblastoma

Morgenstern

Baruchel

Irwin

2013

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

More than half of the patients with high-risk neuroblastoma (NB) will relapse despite intensive multimodal therapy, with an additional 10% to 20% refractory to induction chemotherapy. Management of these patients is challenging, given disease heterogeneity, resistance, and organ toxicity including poor hematological reserve. This review will discuss the current treatment options and consider novel therapies on the horizon. Cytotoxic chemotherapy regimens for relapse and refractory NB typically center on the use of the camptothecins, topotecan and irinotecan, in combination with agents such as cyclophosphamide and temozolomide, with objective responses but poor long-term survival. I-meta-iodobenzylguanidine therapy is also effective for relapsed patients with meta-iodobenzylguanidine-avid disease, with objective responses in a third of cases. Immunotherapy with anti-GD2 has recently been incorporated into upfront therapy, but its role in the relapse setting remains uncertain, especially for patients with bulky disease. Future cell-based immunotherapies and other approaches may be able to overcome this limitation. Finally, many novel molecularly targeted agents are in development, some of which show specific promise for NB. Successful incorporation of these agents will require combinations with conventional cytotoxic chemotherapies, as well as the development of predictive biomarkers, to ultimately personalize approaches to patients with "targetable" molecular abnormalities.

show abstract

“…Further analyses have revealed that mismatches for natural killer (NK) cell KIR/KIRligand genotypes and polymorphisms in the Fcγ receptor have also been associated with better responses to anti-GD2 immunotherapy [142,143]. With the significant side effects and known limitations of anti-GD2 antibody immunotherapy, many other immunologic approaches have been evaluated recently, including therapy with immunomodulatory CTLA4 checkpoint inhibitors [144], antitumor vaccines [145,146], and cell-based immunotherapy using either NK cells [147] or anti-GD2 targeted autologous T cells [148], which have been shown to have antitumor activity, including activity in cases with measurable disease [149,150]. Next-generation chimeric antigen receptor T cells, in which the constructs will include costimulatory domains to activate the T cell, are currently being developed [151].…”

Section: Treatment -Relapsed and Refractory Neuroblastomamentioning

confidence: 99%

Overview and recent advances in the treatment of neuroblastoma

Whittle

Smith

Doherty

et al. 2017

Expert Review of Anticancer Therapy

325

258

View full text Add to dashboard Cite

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.ARTICLE HISTORY

show abstract

NK Cell immunotherapy for high‐risk neuroblastoma relapse after haploidentical HSCT

Cited by 32 publications

References 12 publications

Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma

Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma

Current and Future Strategies for Relapsed Neuroblastoma

Overview and recent advances in the treatment of neuroblastoma

Contact Info

Product

Resources

About